Caribou Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Caribou Biosciences (CRBU).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

5Buy

5Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$9Upside to Avg. PT+1907.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	—
Oct 7, 2026	Brookline Capital	Leah Cann	Downgrade	Buy→Hold	—
Oct 7, 2026	RBC Capital	Luca Issi	Downgrade	Outperform→Sector Perform	$10→$1
Oct 7, 2026	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	$4→$1
Aug 14, 2026	B of A Securities	Alec Stranahan	PT Cut	Buy	$6→$5
May 11, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$9→$11
Apr 7, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$9
Mar 9, 2026	Evercore ISI Group	Jonathan Miller	PT Raise	Outperform	$11→$13
Feb 2, 2026	Clear Street	Bill Maughan	Initiate	Buy	$13
Nov 5, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$3→$9
Nov 3, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$5→$8
Apr 28, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$9→$3
Mar 19, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$9
Jan 7, 2025	B of A Securities	Alec Stranahan	PT Cut	Buy	$13→$11
Nov 26, 2024	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$30→$6
Nov 15, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$9
Sep 3, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$9
Aug 14, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$9
Aug 7, 2024	RBC Capital	Luca Issi	Maintained	Outperform	$14
Jul 17, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$9

Analyst Ratings News

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.

Avi Kapoor

This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Analysts downgraded STZ, TYL, DK, CRBU and PSX; price targets changed for STZ, TYL, DK and PSX.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Neutral.

Benzinga Newsdesk

This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

Analysts downgraded PJT, OPCH, CRBU, ABEV , cutting price targets for PJT, CRBU.

Avi Kapoor

PRO
Brookline Capital Downgrades Caribou Biosciences to Hold

Brookline Capital analyst Leah Cann downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Hold.

Benzinga Newsdesk

PRO
RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1

RBC Capital analyst Luca Issi downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Sector Perform and lowers the price target from $10 to $1.

Benzinga Newsdesk

Caribou Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Caribou Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PRO
HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral

This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

PRO
Brookline Capital Downgrades Caribou Biosciences to Hold

PRO
RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1

People Also Watch

People Also Watch

Caribou Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Caribou Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PROHC Wainwright & Co. Downgrades Caribou Biosciences to Neutral

This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

PROBrookline Capital Downgrades Caribou Biosciences to Hold

PRORBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral

PRO
Brookline Capital Downgrades Caribou Biosciences to Hold

PRO
RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1